The altered immune states of aging and HIV infection may affect intracellular metabolism of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC); increased cellular senescence decreases FTC-triphosphate (FTCtp) concentrations. The effects of age and inflammation on the ratio of intracellular metabolites (IM; tenofovir diphosphate [TFVdp], FTCtp) to their endogenous nucleotides (EN; dATP and dCTP, respectively), a potential treatment efficacy marker, was assessed among participants of the Women's Interagency HIV Study (WIHS), who ranged from 25-75 years. Samples from women receiving TDF/FTC with viral load <200 copies/mL were dichotomized by age at collection into two groups (≤45 years, ≥60 years). IM/EN concentrations were measured in peripheral blood mononuclear cell (PBMC) pellets; IL-6 and sCD163 were measured in plasma; senescent CD8+ T cells were measured in viable PBMCs. The TFVdp:dATP and FTCtp:dCTP ratios had statistically significantly different distributions in older and younger women (log-rank test p=0.0023 and p=0.032, respectively); in general, IM and EN concentrations were higher in the older women. After adjusting for potential confounders, these findings were not significant. In women ≤45 years, TFVdp was negatively associated with IL-6 and sCD163, while FTCtp was positively associated with sCD163 and IL-6 in women ≥60 years. BMI was positively associated with IL-6 in both age groups, and negatively associated with TFVdp in women ≤45 years. After adjustment, age remained significant for sCD163, while Black race, BMI, and renal function remained significant for several IMs and ENs, suggesting that factors associated with aging, but not age itself, govern intracellular TDF/FTC pharmacology.